Cited by 888Menopause: Health Impacts and TreatmentsEstrogen and related hormone effectsCancer Risks and Factors

The DOI matches its Crossref record.

Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin

Ross, R. K.·2000·Journal of the National Cancer Institute

Open this paper in CoChat — free account

Abstract

BACKGROUND: Hormone replacement therapy (HRT) given as unopposed estrogen replacement therapy (ERT) gained widespread popularity in the United States in the 1960s and 1970s. Recent prescribing practices have favored combination HRT (CHRT), i.e., adding a progestin to estrogen for the entire monthly cycle (continuous combined replacement therapy [CCRT]) or a part of the cycle (sequential estrogen plus progestin therapy [SEPRT]). Few data exist on the association between CHRT and breast cancer risk. We determined the effects of CHRT on a woman's risk of developing breast cancer in a population-based, case-control study. METHODS: Case subjects included those with incident breast cancers diagnosed over 4(1/2) years in Los Angeles County, CA, in the late 1980s and 1990s. Control subjects were neighborhood residents who were individually matched to case subjects on age and race. Case subjects and control subjects were interviewed in person to collect information on known breast cancer risk factors as well as on HRT use. Information on 1897 postmenopausal case subjects and on 1637 postmenopausal control subjects aged 55-72 years who had not undergone a simple hysterectomy was analyzed. Breast cancer risks associated with the various types of HRT were estimated as odds ratios (ORs) after adjusting simultaneously for the different forms of HRT and for known risk factors of breast cancer. All P values are two-sided. RESULTS: HRT was associated with a 10% higher breast cancer risk for each 5 years of use (OR(5) = 1.10; 95% confidence interval [CI] = 1.02-1.18). Risk was substantially higher for CHRT use (OR(5) = 1.24; 95% CI = 1.07-1.45) than for ERT use (OR(5) = 1. 06; 95% CI = 0.97-1.15). Risk estimates were higher for SEPRT (OR(5) = 1.38; 95% CI = 1.13-1.68) than for CCRT (OR(5) = 1.09; 95% CI = 0. 88-1.35), but this difference was not statistically significant. CONCLUSIONS: This study provides strong evidence that the addition of a progestin to HRT enhances markedly the risk of breast cancer relative to estrogen use alone. These findings have important implications for the risk-benefit equation for HRT in women using CHRT.

Integrity signals

Registry

Crossref · 10.1093/jnci/92.4.328

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 301–400 of 888

Hormone replacement therapy and breast density changes
Harvey, J. A., Scheurer, C., Kawakami, F., et al. (2005) · Climacteric · doi:10.1080/13697130500103458 · Cited by 36
Effect of Estradiol on Neurotrophin Receptors in Basal Forebrain Cholinergic Neurons: Relevance for Alzheimer’s Disease
Kwakowsky, A., Milne, M., Waldvogel, H. J., & Faull, R. L. M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122122 · Cited by 36
Mammographic density increase in women receiving different hormone replacement regimens
Erel, C. T., Esen, G., Seyisoğlu, H., et al. (2001) · Maturitas · doi:10.1016/s0378-5122(01)00236-5 · Cited by 36
Sex hormones and the risk of keratinocyte cancers among women in the United States: A population‐based case–control study
Kuklinski, L. F., Zens, M. S., Perry, A. E., Gossai, A., Nelson, H. H., & Karagas, M. R. (2016) · International Journal of Cancer · doi:10.1002/ijc.30072 · Cited by 35
Anti-osteoporotic effects of Salvia miltiorrhiza Bunge EtOH extract both in ovariectomized and naturally menopausal mouse models
Lee, S. R., Jeon, H., Kwon, J. E., Suh, H. J., Kim, B., Yun, M., Lim, Y. J., & Kang, S. C. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112874 · Cited by 35
A prospective study on women with a history of breast cancer and with or without estrogen replacement therapy
Marttunen, M. B., Hietanen, P. S., Pyrhönen, S. O., Tiitinen, A. E., & Ylikorkala, O. (2001) · Maturitas · doi:10.1016/s0378-5122(01)00211-0 · Cited by 34
Subtype-specific activation of estrogen receptors by a special extract of Rheum rhaponticum (ERr 731®), its aglycones and structurally related compounds in U2OS human osteosarcoma cells
Möller, F. J., Zierau, O., Jandausch, A., et al. (2007) · Phytomedicine · doi:10.1016/j.phymed.2007.09.001 · Cited by 35
Environmental dichlorodiphenyltrichlorethane or hexachlorobenzene exposure and breast cancer: is there a risk?
Charlier, C., Foidart, J., Pitance, F., Herman, P., GASPARD, U. J., Meurisse, M., & Plomteux, G. J. (2004) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2004.040 · Cited by 35
Natural and Synthetic Progestins Accelerate 7,12-Dimethylbenz[a]Anthracene-Initiated Mammary Tumors and Increase Angiogenesis in Sprague-Dawley Rats
Benakanakere, I., Besch-Williford, C. L., Schnell, J. D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0427 · Cited by 35
Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies
Verheul, H. A. M., Bennink, H. J. T. C., Kenemans, P., Atsma, W. J., Burger, C. W., Eden, J., Hammar, M. L., Marsden, J., & Purdie, D. W. (2000) · Maturitas · doi:10.1016/s0378-5122(00)00150-x · Cited by 35
Hormone-related pathways and risk of breast cancer subtypes in African American women
Haddad, S. A., Lunetta, K. L., Ruiz-Narváez, E., Bensen, J. T., Hong, C., Sucheston‐Campbell, L. E., Yao, S., Bandera, E. V., Rosenberg, L. A., Haiman, C. A., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3594-x · Cited by 34
Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy
Gadducci, A., Biglia, N., Cosio, S., Sismondi, P., & Genazzani, A. R. (2010) · Gynecological Endocrinology · doi:10.3109/09513590.2010.487609 · Cited by 34
Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index: Figure 1.
Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv327 · Cited by 34
Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071
Liang, Y., Besch-Williford, C. L., Aebi, J. D., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2996-5 · Cited by 34
p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells
Liang, Y., Wu, J., Stancel, G. M., & Hyder, S. M. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.12.011 · Cited by 34
Hormone therapy and breast cancer risk
Foidart, J., Desreux, J., Pintiaux, A., & Gompel, A. (2007) · Climacteric · doi:10.1080/13697130701598324 · Cited by 35
Modifiable Risk Factors for Breast Cancer Recurrence: What Can We Tell Survivors?
Norman, S. A., Potashnik, S. L., Galantino, M. L., Michele, A. D., House, L., & Localio, A. R. (2007) · Journal of Women s Health · doi:10.1089/jwh.2006.0047 · Cited by 35
Postmenopausal osteoporosis management
Gambacciani, M., & Ciaponi, M. (2000) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-200006000-00005 · Cited by 34
An Embryonic and Induced Pluripotent Stem Cell Model for Ovarian Granulosa Cell Development and Steroidogenesis
Lipskind, S. T., Lindsey, J. S., Gerami‐Naini, B., Eaton, J. L., O’Connell, D., Kieżun, A., Ho, J. W. K., Ng, N., Parasar, P., Ng, M. C., et al. (2017) · Reproductive Sciences · doi:10.1177/1933719117725814 · Cited by 34
Phytoestrogens: The current state of research emphasizing breast pathophysiology
Senthilkumar, H. A., Fata, J. E., & Kennelly, E. J. (2018) · Phytotherapy Research · doi:10.1002/ptr.6115 · Cited by 34
Clinical Monograph: Hormone Replacement Therapy
Deady, J. (2004) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2004.10.1.33 · Cited by 33
Breast Cancer Risk Reduction: Strategies for Women at Increased Risk
Chlebowski, R. T. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103925 · Cited by 33
Postmenopausal Hormone Therapy and Breast Cancer Prognostic Characteristics: A Linkage between Nationwide Registries
Román, M., Graff‐Iversen, S., Weiderpass, E., Vangen, S., Sakshaug, S., Hofvind, S. S. H., & Ursin, G. (2016) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0240 · Cited by 33
Formation of M1G-dR from endogenous and exogenous ROS-inducing chemicals
Jeong, Y.-C., & Swenberg, J. A. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.05.018 · Cited by 33
Breast cancer incidence trends in Norway—explained by hormone therapy or mammographic screening?
Hofvind, S. S. H., Sakshaug, S., Ursin, G., & Graff‐Iversen, S. (2011) · International Journal of Cancer · doi:10.1002/ijc.26280 · Cited by 31
Hormone replacement therapy and the breast
Dixon, J. M. (2001) · BMJ · doi:10.1136/bmj.323.7326.1381 · Cited by 33
Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin
Colditz, G. A. (2007) · Breast Cancer Research · doi:10.1186/bcr1736 · Cited by 33
Progesterone Receptor Expression in Medroxyprogesterone Acetate-Induced Murine Mammary Carcinomas and Response to Endocrine Treatment
Helguero, L. A., Viegas, M. H., Asaithamby, A., et al. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1024029826248 · Cited by 33
Anabolic-androgenic steroids induce apoptotic cell death in adult rat ventricular myocytes
Zaugg, M., Jamali, N. Z., Lucchinetti, E., Xu, W., Alam, M., Shafiq, S. A., & Siddiqui, M. A. Q. (2001) · Journal of Cellular Physiology · doi:10.1002/1097-4652(2001)9999:9999 · Cited by 106
Postmenopausal hormone therapy and mammographic breast density
Marchesoni, D., Driul, L., Ianni, A., et al. (2005) · Maturitas · doi:10.1016/j.maturitas.2005.02.010 · Cited by 32
Progestins and their effects on the breast
Druckmann, R. A. (2003) · Maturitas · doi:10.1016/j.maturitas.2003.09.020 · Cited by 32
Sex hormones and lipoprotein(a) concentration
Gaeta, G. B., Lanero, S., Barra, S., Silvestri, N., Cuomo, V., Materazzi, C., & Vitagliano, G. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.548804 · Cited by 30
Evidence for the preventive effect of the polyunsaturated phytol side chain in tocotrienols on 17β-estradiol epoxidation
Yu, F., Gapor, A., & Bender, W. (2005) · Cancer Detection and Prevention · doi:10.1016/j.cdp.2005.03.003 · Cited by 31
Breast cancer hypothesis: a single cause for the majority of cases
Wiseman, R. A. (2000) · Journal of Epidemiology & Community Health · doi:10.1136/jech.54.11.851 · Cited by 31
The Combination of a Novel Selective Estrogen Receptor Modulator with an Estrogen Protects the Mammary Gland and Uterus in a Rodent Model: The Future of Postmenopausal Women’s Health?
Labrie, F., Elalfy, M., Berger, L., Labrie, C., Martel, C., Bélanger, A., Candas, B., & Pelletier, G. (2003) · Endocrinology · doi:10.1210/en.2003-0269 · Cited by 31
Use of Oral Conjugated Estrogen Alone and Risk of Breast Cancer
Zhang, S. M., Manson, J. E., Rexrode, K. M., Cook, N. R., Buring, J. E., & Lee, I.-M. M. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwk038 · Cited by 31
Hormone replacement therapy and risk of malignancy
Diamanti‐Kandarakis, E. (2004) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-200402000-00013 · Cited by 31
Apigenin blocks induction of vascular endothelial growth factor mRNA and protein in progestin-treated human breast cancer cells
Mafuvadze, B., Benakanakere, I., & Hyder, S. M. (2010) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181dd052f · Cited by 30
Risk factors for breast cancer
Falkenberry, S. S., & Legare, R. D. (2002) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(03)00059-7 · Cited by 31
Post-Treatment Change in Serum Estrone Predicts Mammographic Percent Density Changes in Women Who Received Combination Estrogen and Progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
Ursin, G., Palla, S. L., Reboussin, B. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.120 · Cited by 30
Hormone replacement therapy and risk of breast cancer: the role of progestins
Stahlberg, C. I., Pedersen, A. T., Lynge, E., & Ottesen, B. (2003) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1034/j.1600-0412.2003.00551.x · Cited by 30
Ductal Carcinoma in Situ (DCIS) of The Breast: Diagnostic and Therapeutic Controversies
Silverstein, M. J., Parker, S. H., Grotting, J. C., Côté, R. J., & Russell, C. A. (2001) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(00)00791-2 · Cited by 30
Exercise and breast cancer prevention
Bernstein, L. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0066-7 · Cited by 30
The menopause, hormone replacement therapy and breast cancer
Marsden, J. (2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(02)00258-3 · Cited by 29
Estrogen and Progesterone Levels in Nipple Aspirate Fluid of Healthy Premenopausal Women: Relationship to Steroid Precursors and Response Proteins
Gann, P. H., Geiger, A. S., Helenowski, I., Vonesh, E. F., & Chatterton, R. T. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0470 · Cited by 29
Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer
Reed, S. D., Voigt, L. F., Beresford, S. A. A., Hill, D. A., Doherty, J. A., & Weiss, N. S. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.04.041 · Cited by 29
Estrogen replacement therapy in patients with early breast cancer
Natrajan, P. K., & Gambrell, R. D. (2002) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2002.125999 · Cited by 29
Exogenous estrogen in systemic lupus erythematosus: oral contraceptives and hormone replacement therapy
Petri, M. (2001) · Lupus · doi:10.1191/096120301676707393 · Cited by 28
The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development
CARROLL, C. E., LIANG, Y., BENAKANAKERE, I., BESCH-WILLIFORD, C., & HYDER, S. M. (2013) · International Journal of Oncology · doi:10.3892/ijo.2012.1675 · Cited by 28
Association of Nongenetic Factors With Breast Cancer Risk in Genetically Predisposed Groups of Women in the UK Biobank Cohort
Al-Ajmi, K., Lophatananon, A., Mekli, K., Ollier, W., & Muir, K. R. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.3760 · Cited by 31
Quercetin alleviates cognitive decline in ovariectomized mice by potentially modulating histone acetylation homeostasis
Aggarwal, A., Sharma, N., Khera, A., Sandhir, R., & Rishi, V. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108439 · Cited by 30
Hormone Therapy and Young-Onset Breast Cancer
O’Brien, K. M., Fei, C., Sandler, D. P., Nichols, H. B., DeRoo, L. A., & Weinberg, C. R. (2015) · American Journal of Epidemiology · doi:10.1093/aje/kwu347 · Cited by 28
Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: A debated clinical issue
Gadducci, A., Biglia, N., Cosio, S., Sismondi, P., & Genazzani, A. R. (2009) · Gynecological Endocrinology · doi:10.3109/09513590903056878 · Cited by 28
Age of menarche is associated with knee joint replacement due to primary osteoarthritis (The HUNT Study and the Norwegian Arthroplasty Register)
Hellevik, A. I., Nordsletten, L., Johnsen, M. B., Fenstad, A. M., Furnes, O. N., Storheim, K., Zwart, J., Flugsrud, G. B., & Langhammer, A. (2017) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2017.06.010 · Cited by 27
The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits – an attempt to interpret the Women's Health Initiative results
Kühl, H., & Stevenson, J. C. (2006) · Gynecological Endocrinology · doi:10.1080/09513590600717368 · Cited by 28
Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy
Chlebowski, R. T., Kim, J. A., & Col, N. F. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.021 · Cited by 28
Transcriptional profiles of progestogen effects in the postmenopausal breast
Wood, C. E., Register, T. C., & Cline, J. M. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0003-8 · Cited by 28
Antisense oligonucleotides targeting the progesterone receptor inhibit hormone-independent breast cancer growth in mice
Lamb, C. A., Helguero, L. A., Giulianelli, S., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1345 · Cited by 28
HRT Opposed to Low-Dose Tamoxifen (HOT Study): Rationale and Design
DeCensi, A., Galli, A., & Veronesi, U. (2003) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-55647-0_10 · Cited by 27
Cytoskeletal responsiveness to progestins is dependent on progesterone receptor A levels
McGowan, E. M., Weinberger, R. P., Graham, J. D., et al. (2003) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0310241 · Cited by 28
Cell Fate Decisions During Breast Cancer Development
Gross, K. M., Wronski, A., Skibinski, A., Phillips, S. M., & Kuperwasser, C. (2016) · Journal of Developmental Biology · doi:10.3390/jdb4010004 · Cited by 27
Inhibitory Effects of Rhaponticin on Osteoclast Formation and Resorption by Targeting RANKL-Induced NFATc1 and ROS Activity
He, J., Chen, K., Deng, T., Xie, J., Zhong, K., Yuan, J., Wang, Z., Xiao, Z., Gu, R., Chen, D., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.645140 · Cited by 27
Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study
Cicinelli, E., de Ziegler, D., Alfonso, R., Nicoletti, R., Bellavia, M., & Colafiglio, G. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.01.095 · Cited by 27
Ligand- and Cell-Specific Effects of Signal Transduction Pathway Inhibitors on Progestin-Induced Vascular Endothelial Growth Factor Levels in Human Breast Cancer Cells
Wu, J., Brandt, S., & Hyder, S. M. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0252 · Cited by 27
Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer.
Pritchard, K. I., Khan, H., & Levine, M. (2002) · PubMed Central · Cited by 27
Low-dosage esterified estrogens opposed by progestin at 6-month intervals
Ettinger, B. B. (2001) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(01)01419-3 · Cited by 27
Estrogen Induces a Systemic Growth Factor Through an Estrogen Receptor-Alpha-Dependent Mechanism1
Bigsby, R. M., Caperell–Grant, A., Berry, N. B., Nephew, K. P., & Lubahn, D. B. (2004) · Biology of Reproduction · doi:10.1095/biolreprod.103.021337 · Cited by 27
Estradiol Modulation of Neurotrophin Receptor Expression in Female Mouse Basal Forebrain Cholinergic Neurons In Vivo
Milne, M., Haug, C. A., Ábrahám, I. M., & Kwakowsky, A. (2014) · Endocrinology · doi:10.1210/en.2014-1669 · Cited by 30
Postmenopausal hormone therapy and the risk of breast cancer in Norway
Román, M., Sakshaug, S., Graff‐Iversen, S., Vangen, S., Weiderpass, E., Ursin, G., & Hofvind, S. S. H. (2015) · International Journal of Cancer · doi:10.1002/ijc.29810 · Cited by 26
Breast cancer risk associated with different HRT formulations: a register-based case-control study
Dinger, J. C., Heinemann, L. A. J., Möhner, S., et al. (2006) · BMC Women s Health · doi:10.1186/1472-6874-6-13 · Cited by 26
Comprehensive Evaluation of the Older Woman
Amin, S. H., Kuhle, C. L., & Fitzpatrick, L. A. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.9.1157 · Cited by 27
Three novel hormone‐responsive cell lines derived from primary human breast carcinomas: Functional characterization
Vázquez, S. M., Mladovan, A., Garbovesky, C., et al. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10466 · Cited by 26
Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells
Shields-Botella, J., Chetrite, G. S., Meschi, S., & Pasqualini, J. R. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.11.004 · Cited by 25
Progesterone regulates catechol-O-methyl transferase gene expression in breast cancer cells: Distinct effect of progesterone receptor isoforms
Salama, S. A., Jamaluddin, M., Kumar, R., Hassan, M. H., & Al-Hendy, A. A. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.03.049 · Cited by 26
Postmenopausal hormone therapy and the risk of breast cancer
Speroff, L. (2008) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31812f7b55 · Cited by 26
Comparison of the effect of progesterone, medroxyprogesterone acetate and norethisterone on the proliferation of human breast cancer cells
Seeger, H., Wallwiener, D. R., & Mueck, A. O. (2003) · The Journal of the British Menopause Society · doi:10.1258/136218003100322008 · Cited by 26
Effects of estradiol with oral or intravaginal progesterone on risk markers for breast cancer in a postmenopausal monkey model
Wood, C. E., Sitruk-Ware, R. L., Tsong, Y. Y., Register, T. C., Lees, C. J., & Cline, J. M. (2007) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000247017.41007.80 · Cited by 26
Combined effect of oral contraceptive use and hormone replacement therapy on breast cancer risk in postmenopausal women
Norman, S. A., Berlin, J. A., Weber, A. L., Strom, B. L., Daling, J. R., Weiss, L. K., Marchbanks, P. A., Bernstein, L., Voigt, L. F., McDonald, J. A., et al. (2003) · Cancer Causes & Control · doi:10.1023/b:caco.0000007967.25865.29 · Cited by 27
The SOGC Statement on the WHI Report On Estrogen and Progestin Use in Postmenopausal Women
Blake, J. M., Collins, J. A., Reid, R. L., et al. (2002) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)30471-6 · Cited by 26
More About: Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin
Magnusson, C. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.14.1183 · Cited by 26
Exogenous progestagens and the human breast
Sitruk-Ware, R. L., & Plu‐Bureau, G. (2004) · Maturitas · doi:10.1016/j.maturitas.2004.06.007 · Cited by 26
Clinical background of women prescribed tibolone or combined estrogen + progestogen therapies: a UK MediPlus® study
Wierik, E. V.-T., Hendricks, P., & Boerstoel-Streefland, M. (2004) · Climacteric · doi:10.1080/13697130410001713724 · Cited by 26
Synthetic Progestins Differentially Promote or Prevent 7,12-Dimethylbenz(a)anthracene–Induced Mammary Tumors in Sprague-Dawley Rats
Benakanakere, I., Besch-Williford, C. L., Carroll, C. E., & Hyder, S. M. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0064 · Cited by 25
Fertility and the impact of systemic therapy on hormonal status following treatment for breast cancer
Moore, H. C. F. (2000) · Current Oncology Reports · doi:10.1007/s11912-000-0114-9 · Cited by 25
Effects of progestogens on the postmenopausal breast
Lignieres, B. D. (2002) · Climacteric · doi:10.1080/713605271 · Cited by 25
Impact of hormone replacement therapy on endogenous estradiol metabolism in postmenopausal women
Mueck, A. O., Seeger, H., & Wallwiener, D. R. (2002) · Maturitas · doi:10.1016/s0378-5122(02)00160-3 · Cited by 25
Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment.
Gram, I., Ursin, G., SPICER, D. V., et al. (2001) · PubMed · Cited by 25
Hormone Replacement in Women with a History of Breast Cancer
Pritchard, K. I. (2001) · The Oncologist · doi:10.1634/theoncologist.6-4-353 · Cited by 25
Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women
Archer, D. F., Hendrix, S. L., Ferenczy, A. S., Felix, J., Gallagher, J. C., RYMER, J. M., Skouby, S. O., den Hollander, W., Stathopoulos, V. M., & Helmond, F. A. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.12.052 · Cited by 24
Genetic Variation in the Progesterone Receptor and Metabolism Pathways and Hormone Therapy in Relation to Breast Cancer Risk
Reding, K. W., Li, C. I., Weiss, N. S., Chen, C., Carlson, C. S., Duggan, D. J., Thummel, K. E., Daling, J. R., & Malone, K. E. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp298 · Cited by 23
Targeting Progesterone Receptors in Breast Cancer
Giulianelli, S., Molinolo, A., & Lanari, C. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-416673-8.00009-5 · Cited by 24
Steroid receptor coactivator 2 is essential for progesterone-dependent uterine function and mammary morphogenesis: Insights from the mouse—implications for the human
Mukherjee, A., Amato, P., Allred, D. C., Fernandez‐Valdivia, R., Nguyen, J., O’Malley, B. W., DeMayo, F. J., & Lydon, J. P. (2006) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.09.007 · Cited by 24
Current breast cancer risks of hormone replacement therapy in postmenopausal women
Shah, N. R., & Wong, T. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.18.2455 · Cited by 24
Unopposed Estradiol Therapy in Postmenopausal Women
Steiner, A. Z., Xiang, M., Mack, W. J., Shoupe, D., Felix, J. C., Løbo, R. A., & Hodis, H. N. (2007) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000251518.56369.eb · Cited by 24
Reversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapy
Figueroa-Casas, P. R., Ettinger, B. B., Delgado, E., Javkin, A., & Vieder, C. (2001) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-200111000-00006 · Cited by 24
Environmental carcinogens and p53 tumor‐suppressor gene interactions in a transgenic mouse model for mammary carcinogenesis
Medina, D. J., Ullrich, R. L., Meyn, R. E., et al. (2002) · Environmental and Molecular Mutagenesis · doi:10.1002/em.10064 · Cited by 24
Traditional Breast Cancer Risk Factors in Filipina Americans Compared with Chinese and Japanese Americans in Los Angeles County
Wu, A. H., Vigen, C. L. P., Lee, E., Tseng, C.-C., & Butler, L. M. (2016) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0203 · Cited by 23
The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer
Sprague, B. L., Trentham‐Dietz, A., & Remington, P. (2010) · Cancer Causes & Control · doi:10.1007/s10552-010-9682-7 · Cited by 23
Progesterone-induced stimulation of mammary tumorigenesis is due to the progesterone metabolite, 5α-dihydroprogesterone (5αP) and can be suppressed by the 5α-reductase inhibitor, finasteride
Wiebe, J. P., Rivas, M. A., Mercogliano, M. F., et al. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.01.004 · Cited by 23
Postmenopausal Female Hormone Use and Estrogen Receptor–Positive and –Negative Breast Cancer in African American Women
Rosenberg, L. A., Bethea, T. N., Viscidi, E., Hong, C., Troester, M. A., Bandera, E. V., Haiman, C. A., Kolonel, L. N., Olshan, A. F., Ambrosone, C. B., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv361 · Cited by 23

Authors: Ross, R. K.
Affiliations: USC Norris Comprehensive Cancer Center (US)
Corresponding author: Ross, R. K.
Venue: Journal of the National Cancer Institute
Publisher: Oxford University Press (OUP)
Published: 2000-02-16
Volume: 92
Issue: 4
Pages: 328-332
ISSN: 0027-8874 (ISSN-L)
1460-2105
DOI: 10.1093/jnci/92.4.328
OpenAlex: W3022279537
Cited by: 877
References: 0
Citations by year: 2026: 4 · 2025: 9 · 2024: 2 · 2023: 9 · 2022: 8 · 2021: 14 · 2020: 17 · 2019: 8 · 2018: 14 · 2017: 14 · 2016: 16 · 2015: 21 · 2014: 21 · 2013: 28 · 2012: 30
FWCI: 73.78
Type: journal article
Language: en
Open access: closed
Locations: JNCI Journal of the National Cancer Institute (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (n01pc067010-004)
National Cancer Institute (CA 17054, P01CA017054, CA14089, P30CA014089, PC67010)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Oncology › Cancer Risks and Factors
Keywords: hormone replacement therapy, breast cancer risk, estrogen plus progestin, postmenopausal women, hormone-dependent breast cancer, breast cancer risk factors, duration of HRT use, Los Angeles
MeSH terms: Aged, Breast Neoplasms, California, Estrogens, Female, Humans, Middle Aged, Progestins, Risk, Risk Factors, Time Factors, Estrogen Replacement Therapy, Odds Ratio, Case-Control Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks